World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 12 December 2020
Main ID:  NCT03704610
Date of registration: 10/10/2018
Prospective Registration: Yes
Primary sponsor: Assistance Publique - Hôpitaux de Paris
Public title: Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES) EFIRTES
Scientific title: Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES STUDY)
Date of first enrolment: March 28, 2019
Target sample size: 30
Recruitment status: Recruiting
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Investigator).  
Phase:  Phase 3
Countries of recruitment
Name:     Anne Bissery
Telephone: 1 42 16 24 32
Name:     Fleur COHEN AUBART, MCU-PH
Telephone: 142178242
Name:     Fleur COHEN AUBART, MCU-PH
Affiliation:  APHP - Hôpital Pitié-Salpêtriere, Paris,France
Key inclusion & exclusion criteria

Inclusion Criteria:

- Clinical and radiological presentation confirming sarcoidosis

- Presence of non caseating granuloma in at least one organ

- Presence of at least one extrathoracic localization, including hypercalcemia

- Exclusion of other causes of granuloma

- Presence of serious organ involvement or relapse/apparition of a new localization
despite a first-line immunosuppressive drug

- Age superior or equal to 18 years

Exclusion Criteria:

- Pregnancy or breast feeding or women in age of pregnancy without efficient

- Patients with multiple sclerosis

- Patients with prior history of any cancer in the 5 years before inclusion (except for
cutaneous basocellular cancers),

- Patients with a history of hypersensitivity to infliximab to other murine proteins, or
to any of the excipients

- Patients with untreated tuberculosis or current other severe infections such as
sepsis, abscesses, and opportunistic infections• Patients with moderate or severe
heart failure (NYHA class III/IV)

- Concurrent vaccination with live vaccines during therapy

- Inability to understand information about the protocol

- Adult subject under legal protection or unable to consent.

- No informed consent

- Absence of affiliation to National French social security system

- Patients with severe renal failure, severe hepatic impairment, hepatocellular
insufficiency, chronic respiratory insufficiency, risk of angle closure glaucoma, risk
of urinary retention related to urethroprostatic disorders, certain evolving viral
diseases (including hepatitis, herpes, varicella, zoster), psychotic states still not
controlled by treatment

Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Extrathoracic Sarcoidosis
Drug: Infliximab
Drug: Placebo
Primary Outcome(s)
Percentage of patients [Time Frame: week 6]
Secondary Outcome(s)
Percentage of patients [Time Frame: week 16 for experimental arm ; week 22 for control arm]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history